PRESS RELEASE December 11, 2017

Immune Pharmaceuticals Appoints John Zhang, MD, PhD as Vice President, Research and Development

Englewood Cliffs, NJ, USA – December 11, 2017 – Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that it has appointed John Zhang, MD, PhD to the position of Vice President, Research and Development. Dr. Zhang will have oversight […]

Keep Reading

December 11, 2017

Immune Pharmaceuticals Appoints John Zhang, MD, PhD as Vice President, Research and Development

Englewood Cliffs, NJ, USA – December 11, 2017 – Immune Pharmaceuticals Inc. (NASDAQ First North: IMNP) (the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that it has appointed John Zhang, MD, PhD to the position of Vice President, Research and Development. Dr. Zhang will […]

Keep Reading

November 27, 2017

Immune Provides Update Regarding NASDAQ US Listing and Departure of Officer

Englewood Cliffs, New Jersey, USA – November 27, 2017 – Immune Pharmaceuticals Inc. (the “Company”) announced today the public disclosure of certain information regarding its continued listing on NASDAQ US and the departure of its VP Finance. Notice of Compliance with NASDAQ US Listing Rule On August 23, 2017, the Company received a letter from […]

Keep Reading

November 17, 2017

Immune Pharmaceuticals Announces Third Quarter 2017 Financial Results and Provides a Corporate Update

Englewood Cliffs, NJ – November 15, 2017 – Immune Pharmaceuticals Inc. (Nasdaq First North: IMNP) (“Immune”) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced financial results for the quarter ending September 30, 2017 and provided a corporate update. Third Quarter 2017 and Recent Highlights On October […]

Keep Reading

PRESS RELEASE November 15, 2017

Immune Pharmaceuticals Announces Third Quarter 2017 Financial Results and Provides a Corporate Update

Englewood Cliffs, NJ – November 15, 2017 – Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (“Immune”) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced financial results for the quarter ending September 30, 2017 and provided a corporate update. Third Quarter 2017 and Recent Highlights On October 23, we […]

Keep Reading

PRESS RELEASE October 23, 2017

Immune Pharmaceuticals Inc. Announces Closing of $18,000,000 Public Offering of Convertible Preferred Stock and Warrants

October 23, 2017 12:09 PM Eastern Daylight Time ENGLEWOOD CLIFFS, N.J.–(BUSINESS WIRE)–Immune Pharmaceuticals Inc. (“Immune”) (NASDAQ: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced the closing of its previously announced public offering of units for gross proceeds of $18,000,000, which excludes underwriting discounts and commissions […]

Keep Reading

PRESS RELEASE October 19, 2017

Immune Pharmaceuticals Inc. Announces Pricing of $18,000,000 Public Offering of Convertible Preferred Stock and Warrants

October 19, 2017 09:00 AM Eastern Daylight Time ENGLEWOOD CLIFFS, N.J.–(BUSINESS WIRE)–Immune Pharmaceuticals Inc. (“Immune”) (NASDAQ: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced the pricing of an underwritten public offering of units for gross proceeds of $18,000,000, which excludes underwriting discounts and commissions and […]

Keep Reading

PRESS RELEASE October 18, 2017

Immune Pharmaceuticals Announces Presentation at The Liver Meeting 2017

Poster demonstrates activity of anti-eotaxin-1 antibodies in an animal model of immune-mediated hepatitis October 11, 2017 08:45 AM Eastern Daylight Time ENGLEWOOD CLIFFS, N.J.–(BUSINESS WIRE)–Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced that the results of a study investigating the therapeutic […]

Keep Reading

NEWS September 28, 2017

Immune’s rare skin disease drug maintains shine

Story in BioWorld by Michael Fitzhugh. Preliminary data on three additional patients enrolled in a small open-label study of Immune Pharmaceuticals Inc.’s bertilimumab, an experimental treatment for the rare blistering disease bullous pemphigoid (BP), continued to suggest it may offer an effective alternative to systemic corticosteroids, a standard but imperfect therapy for the condition. Immune, which is seeking an […]

Keep Reading

PRESS RELEASE September 27, 2017

Immune Pharmaceuticals Announces Positive Results from Ongoing Phase 2 Trial of Bertilimumab in Bullous Pemphigoid

Results from six subjects demonstrate a large and statistically significant reduction in bullous pemphigoid activity despite aggressive prednisone tapering, with no serious adverse events. September 27, 2017 08:00 AM Eastern Daylight Time ENGLEWOOD CLIFFS, N.J.–(BUSINESS WIRE)–Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today […]

Keep Reading